Wilson Sonsini Goodrich & Rosati's legacy closely traces the birth and evolution of Silicon Valley.
For nearly six decades, Wilson Sonsini has represented the technology pioneers associated with virtually every milestone innovation.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Leading Matters
Client Highlights
Wilson Sonsini Advises on Monte Rosa Therapeutics’ $96 Million Series B Financing
On September 24, 2020, Monte Rosa Therapeutics, a biotechnology company developing precision medicines to degrade disease-causing proteins, announced the closing of a $96 million Series B financing. The financing was led by Aisling Capital with participation from founding investor Versant Ventures and existing investor New Enterprise Associates (NEA). Wilson Sonsini Goodrich & Rosati advised NEA in the transaction.
Client Highlights
Wilson Sonsini Advises Gauss in Collaboration with Cellex to Produce Smartphone-Powered Coronavirus Test
On September 17, 2020, diagnostic maker Cellex announced plans to develop a rapid coronavirus infection test that people can fully perform at home, from sample collection to result—with 15-minute readings double-checked by a personal smartphone app. The company is partnering with Gauss Surgical, a developer of machine vision-based software programs, to help digitize the results of its upcoming COVID-19 antigen test. Wilson Sonsini Goodrich & Rosati advised Gauss with respect to the arrangement.
Client Highlights
Wilson Sonsini Advises Libra Therapeutics in Launch, $29 Million Series A
On September 23, 2020, Libra Therapeutics launched to develop novel drug candidates focused on restoring the cellular balance lost in neurodegenerative diseases. These include amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), which are both characterized by disequilibrium caused by the production and decreased clearance of neurotoxic proteins. In conjunction with the company’s launch, Libra Therapeutics has secured $29 million in Series A financing co-led by Boehringer Ingelheim Venture Fund (BIVF), Epidarex Capital, and Santé. The round was joined by Yonjin Venture, Dolby Family Ventures, and Sixty Degree Capital. Wilson Sonsini Goodrich & Rosati has advised Libra Therapeutics since its formation and represented the company in the Series A transaction.
Client Highlights
Wilson Sonsini Advises Loop Industries in Pricing of $24 Million Underwritten Public Offering
On September 21, 2020, Loop Industries, Inc., a leading innovator in sustainable plastics technology, announced the pricing of an underwritten public offering of 1,880,000 shares of its common stock at a price to the public of $12.75 per share pursuant to an effective Registration Statement on Form S-3 filed with the U.S. Securities and Exchange Commission. In addition, Loop Industries has granted the underwriter a 30-day option to purchase up to an additional 282,000 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $24.0 million. The offering is expected to close on or about September 23, 2020, subject to customary closing conditions. Loop Industries intends to use the net proceeds from the proposed offering for working capital and general corporate purposes, including continued investment in research and development for further innovation and funding ongoing operations.
Client Highlights
Wilson Sonsini Represents Athira Pharma, Inc. in its Initial Public Offering
On September 17, 2020, Athira Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, priced its initial public offering of 12 million shares of its common stock at $17.00 per share. All shares were offered by Athira. The gross proceeds are expected to be $204 million, before deducting underwriting discounts and commissions and estimated offering expenses. Wilson Sonsini represented Athira in connection with the offering.
News Articles
Moe Fodeman and Michael Sommer Recognized as New York Trailblazers
The New York Law Journal recently named Wilson Sonsini partners Moe Fodeman and Michael Sommer to its 2020 list of New York Trailblazers. The list highlights 51 New York-based attorneys recognized as “agents of change” in law.
The Entrepreneurs Report - 1H 2020
This edition of The Entrepreneurs Report offers an analysis of venture financing transactions and bridge loans in which the firm was involved during Q2 2020. This issue also includes an interview that Stacy Kim recently conducted with Benedict Evans, a London-based independent analyst and venture partner at both Mosaic Ventures and Entrepreneur First.meframe.
